戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ells/microL, irrespective of the presence of mucosal infection.
2 ll be influenced strongly by the presence of mucosal infection.
3  vector-borne transmission to study T. cruzi mucosal infection.
4  important sentinel cells in defense against mucosal infection.
5 ty may display differential activity against mucosal infection.
6  cells and are avirulent in animal models of mucosal infection.
7  protective mechanisms, especially following mucosal infection.
8 soluble CD154 (CD40L) concomitant with their mucosal infection.
9 ibody can play an important role in clearing mucosal infection.
10 HIV/Simian Immunodeficiency Virus (SIV) oral mucosal infection.
11 responses associated with protection against mucosal infection.
12 st genital HSV-2 disease but did not prevent mucosal infection.
13 eased risk of HIV-1 transmission at sites of mucosal infection.
14  CCR5 and CXCR4 together inhibited localized mucosal infection.
15 isease with either virus but did not prevent mucosal infection.
16 urrent disease in guinea pigs that developed mucosal infection.
17 munodeficiency virus (HIV and SIV) following mucosal infection.
18 ere significantly protected against T. cruzi mucosal infection.
19 on and the ensuing immune response following mucosal infection.
20  to shape diverse susceptibilities to future mucosal infections.
21 tical step in the pathogenesis of chlamydial mucosal infections.
22 ee strains of immunocompetent mice supported mucosal infections.
23  main bacterial species causing oral and gut mucosal infections.
24 es to provide competitive advantage in human mucosal infections.
25  critical antiviral effectors in hepatic and mucosal infections.
26 erapy to treat microbial keratitis and other mucosal infections.
27 smission by reducing viral extinction during mucosal infections.
28 birth, leading to a higher susceptibility to mucosal infections.
29 veloping effective vaccines against skin and mucosal infections.
30 nstrating the importance of fungal burden in mucosal infections.
31 ects in innate immunity associated with such mucosal infections.
32           H. influenzae causes predominantly mucosal infections.
33 protection from H. pylori and possibly other mucosal infections.
34 vaccines are available for the prevention of mucosal infections.
35 rapidly disintegrates biofilms-a hallmark of mucosal infections.
36 , and has broad applicability for a study of mucosal infections.
37 e is a major cause of otitis media and other mucosal infections.
38 an increased rate, severity, and duration of mucosal infections.
39 ent vulvovaginal candidiasis (VVC), a common mucosal infection affecting significant numbers of women
40 zi is a protozoan parasite that can initiate mucosal infection after conjunctival exposure.
41 e study of protective immunity to chlamydial mucosal infection and for the identification of chlamydi
42 ansmission of EVD, including early events in mucosal infection and immunity, as well as the establish
43 s of strain-specific differences in reovirus mucosal infection and systemic dissemination have enhanc
44 esponses in an acute superficial respiratory mucosal infection and their implications in development
45 hat can be used to study the pathogenesis of mucosal infection and to evaluate the efficacy of vaccin
46 nding facilitates our understanding of HIV-1 mucosal infection and will benefit the development of st
47                SLT patients report increased mucosal infections and allergic disease compared to age-
48 muPV1) model that induces both cutaneous and mucosal infections and cancers.
49 set and activity of IgAN often coincide with mucosal infections and dysregulation of cytokines, we hy
50 hogen of humans, can cause both debilitating mucosal infections and fatal invasive infections.
51 impairs host defense mechanisms that control mucosal infections and inhibits the mechanisms that cont
52 ber of the mucosal microbiota, but can cause mucosal infections and life-threatening disseminated inv
53 ungal pathogen of humans causing superficial mucosal infections and life-threatening systemic disease
54 portunistic fungal pathogen that causes both mucosal infections and life-threatening systemic infecti
55 athogen in humans, causing both debilitating mucosal infections and potentially life-threatening syst
56 d as recurrent sinopulmonary, cutaneous, and mucosal infections and refractory autoimmune cytopenias.
57 f healthy humans, it is also responsible for mucosal infections and severe invasive disease.
58 is in multiple U.S. cities since 2015, other mucosal infections, and cases of invasive meningococcal
59 atening, and an additional half a billion of mucosal infections annually.
60 ector CD8 T cell response, both systemic and mucosal infection are equally effective in the different
61 ays in which these cells help defend against mucosal infection are only beginning to be understood.
62 nd the resulting increased susceptibility to mucosal infection are poorly understood.
63 , and episodes of gross haematuria following mucosal infections are common; 30% of patients develop p
64  well as alters fungal morphology in a mouse mucosal infection assay.
65 at IL-22 provides a mechanistic link between mucosal infection, B-cell recruitment, and humoral autoi
66 poptosis is important in the pathogenesis of mucosal infections but has not been studied with H. pylo
67 tic view of host-pathogen interaction during mucosal infection, but also allow deeper insight into th
68 2 plays a critical role in defending against mucosal infections, but how IL-22 production is regulate
69 ding of the host-pathogen interactome during mucosal infection by a bacterial pathogen.
70 IL-17RA-mediated responses in the control of mucosal infection by Brucella.
71  plays the more important role in initiating mucosal infection by HIV-1.
72 tative approaches to enhance protection from mucosal infection by improving immune defenses at the mu
73 ermine the role of IgA in protection against mucosal infection by influenza and the value of immuniza
74  significantly protects rhesus macaques from mucosal infection by the highly pathogenic strain SIVmac
75 h binary states opens up new ways to control mucosal infections by a major human pathogen.
76 ide the first direct evidence that transient mucosal infection can induce SIV-specific immunity that
77 aginal candidiasis (VVC) is an opportunistic mucosal infection caused by Candida albicans that affect
78   Vulvovaginal candidiasis (VVC) is a common mucosal infection caused by Candida species in women of
79 n vivo IL-17-dependent responses during oral mucosal infections caused by the human commensal fungus
80 ger mucosal immune responses following prior mucosal infection compared with injections of a parenter
81               To examine the consequences of mucosal infection for the T cell response to orally admi
82 the ideal model system should resemble human mucosal infection if vaccine design is to be effective.
83 tion in 5.9%, typhoid fever in 3.7%, skin or mucosal infection in 1.5%, and meningitis in 0.2%.
84 observed after experimental SARS-CoV-2 upper mucosal infection in a rhesus macaque undergoing low-dos
85            In the current study, we examined mucosal infection in several immunocompetent and immunoc
86             Influenza is a highly contagious mucosal infection in the respiratory tract.
87                     Therefore, resistance to mucosal infection in these monkeys may not be mediated b
88 er may be responsible for protection against mucosal infection in this population of monkeys.
89 mia, neutrophil functions, and opportunistic mucosal infections in HIV.
90 to the immunotherapeutic prevention of other mucosal infections in humans and animals.
91 ex formation and disease exacerbation during mucosal infections in IgAN patients.
92 on than HSV-2 as a cause of oral and genital mucosal infections in young women, but there are importa
93 asymptomatically but also causes respiratory mucosal infections, including otitis media, sinusitis, a
94 tions for understanding host defense against mucosal infections, including the pathogenesis of these
95                                    Preceding mucosal infection induces mucosal immunity, resulting in
96 it is unclear to what degree systemic versus mucosal infection influences the generation of effector
97                           Protection against mucosal infection is therefore achievable by parenteral
98 ystem perceives commensals in the context of mucosal infection is unclear.
99 The primary immunologic defense against many mucosal infections is IgA.
100 al infections in models of both invasive and mucosal infections, making NKG2D an anti-fungal pattern
101 M) cells that accumulate in tissue following mucosal infection may be crucial for long-term immunity.
102                         Studies in the nasal mucosal infection model can be employed to assess the im
103 and HIV-1, and thus validate the SIV-macaque mucosal infection model for HIV-1 vaccine and microbicid
104 ppresses GAS pharyngeal colonization in mice mucosal infection model.
105 ency in cultured murine cells or in a murine mucosal infection model.
106 tion of lung and trachea sections, show that mucosal infection of guinea pigs is an efficient model f
107    Here, the authors show that oropharyngeal mucosal infection of macaques with a high ZIKV dose resu
108  address these we have used a model of local mucosal infection of mice with reovirus.
109              Here, we show that during acute mucosal infection of mice with Toxoplasma gondii, inflam
110 5alpha genotype does not confound results of mucosal infection of rhesus macaques with SIV(mac251).
111  memory T (TRM) cells formed in tissue after mucosal infection or vaccination are crucial for counter
112                                              Mucosal infections pose a significant global health burd
113 vival of apparently self-limited and luminal mucosal infections requires a systemic T cell-dependent
114 i.v. route was not recapitulated following a mucosal infection route.
115                                              Mucosal infections such as acute otitis media remain pre
116 philus influenzae (NTHi) is a major cause of mucosal infections such as otitis media, sinusitis, conj
117 icit systemic immunity that protects against mucosal infections, such as the vaccines for influenza a
118  T-cell responses are important in combating mucosal infections, the generation of such immune respon
119 s, causing diseases ranging from superficial mucosal infections to disseminated, systemic infections
120 n immunocompromised hosts, ranging from mild mucosal infections to lethal disseminated disease.
121  range from relatively-minor superficial and mucosal infections to severe, life-threatening systemic
122 cter pylori infection as a model for chronic mucosal infection, we previously published that IL-21 is
123  virus-specific antibody secretion following mucosal infection were a direct result of pDC-derived ty
124 systemic immune systems and protects against mucosal infection with a virus expressing HIV-1 gp160.
125      We hypothesized that protection against mucosal infection with F. tularensis would be significan
126 mined the importance of monocytes in primary mucosal infection with herpes simplex virus 2 (HSV-2), a
127 es using a physiologically relevant model of mucosal infection with herpes simplex virus type 2.
128  immune responses leading to protection from mucosal infection with highly pathogenic HIV and rapidly
129 n the blood, may prove valuable in combating mucosal infection with HIV-1 and warrants further invest
130 s (CTLs) and protect rhesus macaques against mucosal infection with simian/human immunodeficiency vir
131 n Alum, protect 50% and 80% of macaques from mucosal infection with SIV(mac251) or Simian-Human immun
132 A (IgA) has been implicated in resistance to mucosal infections with bacteria, viruses, and parasites
133 ncluding four macaques who controlled rectal mucosal infection without progressive systemic dissemina

 
Page Top